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A 31-year-old white man with relapsing-remitting multiple sclerosis was referred to the nephrology 
ward by the caregiver neurologist because of the presence of new-onset subnephrotic proteinuria 
(from 0.7–2 g/24 h). He had been diagnosed with relapsing-remitting multiple sclerosis 15 years 
earlier and was initially treated with corticosteroids, followed by interferon beta-1a since 2003. No 
relapses had occurred in the past 3 years, during which he had been in good overall health. 
He is a lean, athletic, young man with a degree in philosophy who works as a consultant and travels 
frequently (mainly throughout Europe). He is normotensive and has no residual neurologic deficit. 
The initial workup showed normal kidneys on ultrasonography, serum creatinine level, 0.83 mg/dl 
(Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate, 112 
ml/min); blood urea nitrogen, 13 mg/dl; normal urine sediment; mild hypercholesterolemia (210 
mg/dl); and hypertriglyceridemia (413 mg/dl). Complement levels, immunoglobulins, and other 
immunologic tests (antinuclear antibody, extractable nuclear antigen, anti–double-stranded DNA, 
and anti-neutrophil cytoplasmic antibody) were within the normal range. HIV and hepatitis B and C 
antigens and antibodies tested negative. Renal biopsy was performed (Figure 1). 
 
What is the diagnosis? 
The Diagnosis | Interferon-related associated thrombotic microangiopathy 
Our patient, despite showing relatively mild proteinuria and preserved kidney function, showed 
severe glomerular involvement with characteristic lesions of thrombotic microangiopathy (TMA), 
including mesangiolysis and double contours in the kidney biopsy sample. One glomerulus showed 
collapsing glomerulopathy. No deposits were seen on immunofluorescent studies of 3 glomeruli. 
The interstitial compartment was normal. The collapsing glomerulopathy was considered most 
likely to be a consequence of TMA (Figures 1 and 2). 
The association between multiple sclerosis and kidney diseases, namely, glomerulonephritis, albeit 
rare, has been previously described, including membranous nephropathy and Goodpasture 
syndrome.1 
Interferon therapy (both alfa and beta) has been associated with renal manifestations. These include 
collapsing glomerulopathy and TMA.2, 3, 4 and 5 In recent reports, interferon-associated TMA was 
associated with an aggressive disease course and progressive and often irreversible renal function 
impairment.4 and 5 
In our patient, interferon beta was discontinued, and a rapid drop in proteinuria was observed (<0.5 
g/d within 4 weeks). Two months after interferon discontinuation, however, the patient experienced 
a severe relapse of optic neuritis, necessitating high doses of corticosteroids followed by 
azathioprine maintenance therapy. 
His blood pressure at last follow-up was normal, and he had a serum creatinine level of 0.9 mg/dl 
and proteinuria of 155 mg/d. 
The pathogenesis of interferon-associated TMA is not fully understood. The antiangiogenic activity 
of interferon may be the trigger for microangiopathy, whereas a report on the association with an 
apolipoprotein L1 high-risk genotype recently suggested the possibility that interferon and the 
receptors that stimulate interferon production could contribute to apolipoprotein L1–associated 
kidney disease, including collapsing glomerulopathy, at least in the African-American population. 
This high-risk genotype, however, was not present in our patient; genotyping was performed by 
targeted sequencing of apolipoprotein L1 exon 7. 
Although nephrotoxicity is rare in patients receiving long-term interferon therapy, the onset of 
hypertension, proteinuria, and renal insufficiency should lead to the consideration of interferon 
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Figure 1. Acute lesions of microangiopathy with mesangiolysis (asterisk) and capillary loop doublecontours 




Figure 2. Ultrastructural features of thrombotic microangiopathy: double contour formation with 
subendothelial widening (arrows),loss of fenestrations of glomerular endothelial cells, and cellular 
interposition in the absence of electron dense deposits. 
 
 
 
 
